Financial Contrast: NLS Pharmaceutics (NASDAQ:NCEL) vs. PolyPid (NASDAQ:PYPD)

NLS Pharmaceutics (NASDAQ:NCEL) and PolyPid (NASDAQ:PYPD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.

Insider and Institutional Ownership

26.5% of PolyPid shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by company insiders. Comparatively, 24.7% of PolyPid shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for NLS Pharmaceutics and PolyPid, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1	0	0	0	1.00
PolyPid	1	0	5	0	2.67

PolyPid has a consensus target price of $12.25, indicating a potential upside of 164.01%. Given PolyPid’s stronger consensus rating and higher possible upside, analysts plainly believe PolyPid is more favorable than NLS Pharmaceutics.

Valuation and Earnings

This table compares NLS Pharmaceutics and PolyPid”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$1.98 million	N/A	N/A
PolyPid	N/A	N/A	-$34.17 million	($2.26)	-2.05

Profitability

This table compares NLS Pharmaceutics and PolyPid’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
PolyPid	N/A	-291.42%	-131.82%

Risk & Volatility

NLS Pharmaceutics has a beta of 0.12, suggesting that its stock price is 88% less volatile than the S&P 500. Comparatively, PolyPid has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.

Summary

PolyPid beats NLS Pharmaceutics on 6 of the 9 factors compared between the two stocks.

About NLS Pharmaceutics

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.